A61K 31/7028
Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
A61K31/7028 (Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages) appears on 4,551 US grants and 8,847 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,551
- Published applications
- 8,847
- Assignees
- 3,458
- Inventors
- 15,797
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 2 | 0 |
| 1987 | 5 | 0 |
| 1988 | 2 | 0 |
| 1989 | 3 | 0 |
| 1990 | 6 | 0 |
| 1991 | 4 | 0 |
| 1992 | 7 | 0 |
| 1993 | 2 | 0 |
| 1994 | 4 | 0 |
| 1995 | 8 | 0 |
| 1996 | 9 | 0 |
| 1997 | 14 | 0 |
| 1998 | 26 | 0 |
| 1999 | 28 | 0 |
| 2000 | 26 | 0 |
| 2001 | 35 | 14 |
| 2002 | 43 | 96 |
| 2003 | 58 | 144 |
| 2004 | 41 | 176 |
| 2005 | 50 | 230 |
| 2006 | 50 | 200 |
| 2007 | 35 | 199 |
| 2008 | 61 | 198 |
| 2009 | 58 | 198 |
| 2010 | 92 | 269 |
| 2011 | 97 | 277 |
| 2012 | 132 | 293 |
| 2013 | 163 | 372 |
| 2014 | 242 | 461 |
| 2015 | 256 | 504 |
| 2016 | 294 | 601 |
| 2017 | 314 | 541 |
| 2018 | 314 | 484 |
| 2019 | 321 | 480 |
| 2020 | 324 | 496 |
| 2021 | 275 | 548 |
| 2022 | 267 | 544 |
| 2023 | 250 | 481 |
| 2024 | 237 | 418 |
| 2025 | 248 | 369 |
| 2026 | 139 | 254 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Medication that protects the intestinal microbiota and their preparation methods and applications6 Oct 2026US 12,751,921 B2University of Science and Technology of China
- Therapeutic uses of inhibitors of the RNA-binding protein HuR6 Oct 2026US 12,751,938 B2University of Kansas
- Bifidobacterium longum CCFM1206 capable of producing sulforaphane and relieving inflammation6 Oct 2026US 12,751,980 B2Jiangnan University
- Aqueous pharmaceutical compositions comprising SGLT-2 inhibitors29 Sep 2026US 12,746,198 B2
- Combinatory treatment29 Sep 2026US 12,746,216 B2Arivin Therapeutics Oy
- Guanidinylated Amphiphilic Tobramycin Derivates and B-Lactam/B-Lactamase Inhibitor Combinations for Treatment of Pseudomonas Aeruginosa Infections8 Oct 2026US 2026/0306524 A1
- Combination therapy glucocorticoids and ginsenoside8 Oct 2026US 2026/0306525 A1Fytagoras
- A combination therapy for cancer treatment8 Oct 2026US 2026/0306633 A1Purdue Research Foundation
- Systems and methods for targeted breast cancer therapies1 Oct 2026US 2026/0294809 A1American University of Sharjah
- Compositions and methodology for delivery of alpha-galactosylceramide compounds1 Oct 2026US 2026/0294822 A1EnGeneIC Molecular Delivery Pty Ltd
Most cited
By later US patents
- Method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid coating layer containing a bioactive factor777US 8,734,831 B2Snu R&Db Foundation · 2014
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Therapeutic inhibitor of vascular smooth muscle cells438US 5,981,568 ANeoRx Corporation · 1999
- Liquid delivery compositions268US 5,780,044 AAtrix Laboratories, Inc. · 1998
- Formulations and methods for providing prolonged local anesthesia261US 5,942,241 AEuro-Celtique S. A. · 1999